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Measuring glucose cerebral 
metabolism in the healthy mouse 
using hyperpolarized 13C magnetic 
resonance
Mor Mishkovsky1,2, Brian Anderson3, Magnus Karlsson4,5, Mathilde H. Lerche4,5,  
A. Dean Sherry3, Rolf Gruetter1,6,7, Zoltan Kovacs3 & Arnaud Comment  2,8
The mammalian brain relies primarily on glucose as a fuel to meet its high metabolic demand. Among 
the various techniques used to study cerebral metabolism, 13C magnetic resonance spectroscopy 
(MRS) allows following the fate of 13C-enriched substrates through metabolic pathways. We herein 
demonstrate that it is possible to measure cerebral glucose metabolism in vivo with sub-second time 
resolution using hyperpolarized 13C MRS. In particular, the dynamic 13C-labeling of pyruvate and lactate 
formed from 13C-glucose was observed in real time. An ad-hoc synthesis to produce [2,3,4,6,6-2H5, 
3,4-13C2]-D-glucose was developed to improve the 13C signal-to-noise ratio as compared to experiments 
performed following [U-2H7, U-13C]-D-glucose injections. The main advantage of only labeling C3 and C4 
positions is the absence of 13C-13C coupling in all downstream metabolic products after glucose is split 
into 3-carbon intermediates by aldolase. This unique method allows direct detection of glycolysis in vivo 
in the healthy brain in a noninvasive manner.
Dynamic in vivo 13C MRS combined with the injection of 13C-enriched substrates is a powerful method for 
studying cerebral intermediary metabolism1. It is well established that, although the energy requirement of the 
brain can be satisfied by the oxidation of other substrates such as ketone bodies, lactate and fatty acids, glucose 
is the main cerebral metabolic fuel2. The improved sensitivity and resolution of high-magnetic field 13C MRS 
has increased the reliability of 13C-enrichment time evolution measurements so that metabolic fluxes can now 
be determined accurately. The temporal resolution currently achievable in the rodent brain upon infusion of 
[1,6-13C2]-D-glucose is around 5 min for detection of 13C labeling in the aliphatic carbons of glutamate, glutamine 
and aspartate, and about 20 min for detection of less concentrated metabolites such as γ-aminobutyrate, alanine 
and lactate3. Other important intermediary metabolites present in low concentration such as pyruvate can simply 
not be detected in the rodent brain by conventional thermally polarized 13C MRS. Over the past few decades, mul-
tiple technological advances have been implemented to overcome the inherent low sensitivity of nuclear magnetic 
resonance (NMR) and MRS4. This lack of sensitivity comes from the fact that the NMR/MRS signal is directly 
proportional to the nuclear spin polarization Pn defined as the relative difference between the populations of the 
different nuclear spin quantum states. This polarization is inherently small at room or body temperature even 
in a magnetic field as high as 9.4T where Pn < 8 × 10−6 for 13C spins at 37 °C. To enable detection of less concen-
trated metabolites in vivo, a tremendous 13C signal enhancement in the biomolecules of interest can be achieved 
using so-called “hyperpolarization” techniques. The development of hyperpolarization, in particular dissolution 
dynamic nuclear polarization (DNP) which can increase the room-temperature 13C polarization of molecules in 
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solution by several orders of magnitude5, leads to the possibility of following uptake and metabolism in vivo in 
real time6. To obtain large polarization enhancements by DNP, it is necessary to prepare frozen glassy solutions 
containing a labeled substrate at high concentration and a few tens of mM of suitable paramagnetic centers as 
polarizing agents. The frozen samples are placed in a polarizer, an instrument operating at moderately large mag-
netic field (~3–7 T) and low temperature (~1 K).
To date, only a restricted number of hyperpolarized 13C MRS brain studies have been performed7, mostly 
using pyruvate as substrate. Three metabolic products, lactate, alanine and bicarbonate8,9, were observed fol-
lowing the injection of [1-13C]pyruvate while glutamate and citrate were detected using hyperpolarized [2-13C] 
pyruvate10. Following the infusion of hyperpolarized [1-13C] acetate, it was also reported that the TCA cycle 
intermediate 2-oxoglutarate can be observed in the rat brain11. Unlike the carbonyl carbon in pyruvate, glucose 
carbons have very short longitudinal relaxation time (T1) (~1–2 s) because of the dipolar-dipolar relaxation of the 
13C nuclear spins by the protons present in the molecule. In the perdeuterated [U-2H7, U-13C6]-D-glucose, the 
intramolecular dipolar-dipolar 13C-1H relaxation is eliminated, which extends the T1s of the glucose carbons to 
~10 s. It was demonstrated that [U-2H7, U-13C6]-D-glucose may be used as a hyperpolarized 13C MRS probe to 
observe glycolytic reactions12–15. Hyperpolarized [U-2H7, U-13C6]-D-glucose and fructose as nutrients allowed 
collecting real-time metabolic data from the appearance of downstream metabolites in glycolysis and central 
carbon metabolism in Escherichia coli and Saccharomyces cerevisiae cells. Perdeuterated [U-13C6]-D-glucose was 
also used to successfully probe glycolysis in human T47D breast cancer cells.
It was recently demonstrated that glycolysis in EL4 tumors in mice can be imaged in vivo with [U-2H7, 
U-13C6]-D-glucose16. While the C1 lactate signal was clearly observable as a doublet, these data also highlighted 
the major drawback of perdeuterated [U-13C6]-D-glucose as a hyperpolarized glycolytic probe: the splitting of the 
lactate signal on top of the short 13C T1 further lowers the signal-to-noise (SNR) ratio. In this particular article, 
it was suggested that developing a 3-, 4-, or 3,4-13C-labeled perdeuterated glucose would lengthen the longitu-
dinal relaxation time of the 13C nuclei by eliminating the 13C-13C homonuclear dipolar relaxation16. In addition, 
this labeling strategy will also metabolize to singly [1-13C]-labeled lactate, improving the detection limits of lac-
tate. The aim of the present study was to show that cerebral glucose metabolism can be measured in vivo using 
hyperpolarized 13C MRS. We demonstrated that several metabolites can be detected in the healthy mouse brain 
following the i.v. injection of hyperpolarized 13C-glucose. We also developed a convenient synthesis to produce 
[2,3,4,6,6-2H5, 3,4-13C2]-D-glucose on a multigram scale and demonstrate that it has improved characteristics as 
a hyperpolarization probe for detecting real-time glucose metabolism.
Results
Synthesis of [2,3,4,6,6-2H5, 3,4-13C2]glucose. Due to the cost of [3,4-13C2]-D-glucose starting material, 
our goal was to develop a simple, high yield route to prepare deuterated glucose. The established methods for the 
deuteration of carbohydrates rely on the replacement of covalently bound hydrogens with deuterium using D2O 
and a transition metal catalyst such as Raney Ni or Ru/C17–21. After careful consideration of the literature data 
and some preliminary experimentation, we adopted the Ru/C method largely because the deuterated Raney Ni 
catalyst required long reaction times, which lead to significant isomerizations and formation of other side prod-
ucts19,22. The synthesis of [2,3,4,6,6-2H5, 3,4-13C2]-D-glucose is outlined in Fig. 1. It is known that prolonged direct 
treatment of glucose with Ru/C, H2 and D2O leads to complete decomposition21. Consequently, we first converted 
[3,4-13C2]-D-glucose to the methyl glucoside (1) under standard conditions by stirring the compound in sulfuric 
acid in methanol at reflux overnight. The resulting methyl glucoside was then dissolved in D2O, the Ru/C cata-
lyst was added, and the reaction mixture was stirred under an atmosphere of hydrogen at 80 °C. This resulted in 
incomplete deuteration largely at the C3 position. Simple removal of the used Ru/C by filtration and adding fresh 
catalyst proved to be an efficient way of increasing the deuteration. This iteration was repeated until the desired 
percent deuteration was achieved (>95% deuteration required three repetitions). The final step of the synthesis 
was the hydrolysis of the glycosidic bond by refluxing the deuterated product in 1 M HCl. The overall yield of the 
desired final product was about 75% starting from [3,4-13C2]-D-glucose.
Liquid-state polarization. Using commercially available DNP hardware, the back calculated liquid-state 13C 
polarization at the time of dissolution was about 30% for αC3 and αC4 for both [2,3,4,6,6-2H5, 3,4-13C2]-D-glucose 
and the perdeuterated, uniformly labeled derivative, while the αC1 13C polarization in the latter compound was 
measured to be 13% (see ref.23, Tables S1 and S2, as well as Fig. S1). The liquid-state T1 values for both compounds 
were measured at 9.4T and room temperature after dissolution with water or D2O. These T1s were determined from 
the fitting of the hyperpolarized magnetization decay curves. As seen from the values displayed in Table 1, the appar-
ent T1s of the 3,4-13C2-labeled and the uniformly labeled derivatives do not differ significantly. Deuteration of the 
solvent increased the T1s by approximately 20%, in agreement with previously reported results in which it was shown 
that dipole-dipole relaxation is the major relaxation mechanism for 13C spins in carbohydrates24.
Figure 1. Synthesis of [2,3,4,6,6-2H5, 3,4-13C2]glucose.
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The liquid-state polarization of hyperpolarized [U-2H7, U-13C6]-D-glucose was measured inside a 
custom-designed injection pump following DNP at 7T/1K, dissolution in D2O and transfer into the bore of a 
9.4T MR scanner, using a previously described method25,26. The polarization was determined by comparing the 
hyperpolarized 13C-glucose signal and its corresponding thermally polarized signal (see example in Fig. S2). The 
average 13C polarization values are presented in Table 2. These correspond to the polarization levels at the time of 
the animal intravenous (i.v.) injection.
In vivo 13C MRS. To optimize signal-to-noise ratio (SNR) of the expected glucose metabolites in the carboxyl 
region of the 13C spectra, in particular [1-13C] lactate and [1-13C] pyruvate, we applied an RF excitation pulse 
designed to excite the glucose resonances by a minute flip angle, while exciting the region of interest with a large 
flip angle (20°) (See Fig. 2A and B). The latter was determined using the following considerations: taking into 
account the published in vivo 13C T1 of perdeuterated [U-13C6] glucose of 9 s16, the maximum SNR that can be 
obtained after summing all spectra recorded with an achievable repetition time (greater or equal to 500 ms) cor-
responds to a flip angle of 20° (see Fig. 8 in ref.27). This strategy allowed following build-up of glucose metabolites 
for more than 30 s.
Subsequent to the injection of perdeuterated [U-13C6]-D-glucose, the formation of a doublet peak 
assigned to the lactate resonance could be readily detected at 183.5 ppm with 50 Hz 13C-13C coupling 
(Fig. 3). In the summed spectrum, two additional doublet peaks were detected: one centered at 171.1 ppm 
with 43 Hz 13C-13C coupling corresponding to the pyruvate C1 resonance and an additional peak centered at 
T1 (s)a [2,3,4,6,6-2H5, 3,4-13C2]-D-glucose T1 (s)a [U-2H7, U-13C6]-D-glucose
C3 C4 C3 C4
H2O D2O H2O D2O H2O D2O H2O D2O
12.0 ± 0.2 13.9 ± 0.4 11.0 ± 0.4 12.1 ± 0.3 10.4 ± 0.3 12.2 ± 0.3 10.9 ± 0.3 12.5 ± 0.3
Table 1. T1 values of C3 and C4 carbons of [2,3,4,6,6-2H5, 3,4-13C2]-D-glucose and [U-2H7, U-13C6]-D-glucose 
in H2O and D2O at 9.4T. The T1 values were determined from the fitting of the hyperpolarized magnetization 
decay curves taking into account the decay by T1 relaxation and RF pulsing. The data were collected using 5 
degree pulse angle and repetition time of 5 s. The samples did not contain Gd3+. aAn average of three runs.
Carbon position (α + β) Polarization %
C1 18.9 ± 1.1
C2–5 22.2 ± 2.1
C6 18.5 ± 2.2
Table 2. Liquid-state polarization measured inside the infusion pump (n = 3).
Figure 2. Effective flip angle during the acquisition of hyperpolarized glucose metabolism in vivo. Summed 
13C spectra recorded in the mouse head following the injection of hyperpolarized [|U-2H7, U-13C6]-D-glucose 
(A) and [2,3,4,6,6-2H5, 3,4-13C2]-D-glucose (B). While the flip angle on the metabolites carboxyl carbon 
resonances is 20° its effect on the glucose resonance is minimal. The effective flip angle on glucose resonances 
was confirmed in phantom measurements.
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around 179.8 ppm with 56 Hz 13C-13C coupling, the latter could either be assigned to the glycolytic interme-
diate [1-13C] 3-phosphoglycerate ([1-13C] 3PG) or to the pentose phosphate pathway intermediate [1-13C] 
6-phosphogluconate ([1-13C] 6PG) (Fig. 4).
When using [2,3,4,6,6-2H5, 3,4-13C2]-D-glucose, the doublet peaks detected at the same frequencies of the 
three glucose metabolites were coalesce into single peaks due to the lack of the 13C-13C coupling. The peak at 
179.8 ppm could then be tentatively assigned to [1-13C] 3PG, (see Fig. 4). The high impurity content of the 
Figure 3. In vivo time evolution of [U-2H7, U-13C6]-D-glucose and its metabolic product [13C3]lactate in the 
mouse head. A 20° flip angle pulse was applied every 0.5 s on the carboxyl region of the spectrum while the 
flip angle was measured to be 1.4° on the substrate region. To improve the SNR every two spectra were added 
leading to actual time resolution of 1 s. Glucose C1 peaks appear at 96.8 ppm (C1-β) and 93 ppm (C1-α), lactate 
is observed at 183.5 ppm and can be identified 10.5 s after the infusion (bottom). The corresponding time course 
(inset) of the spectral data that was quantified using AMARES while fitting the lactate doublet to two separated 
peaks.
Figure 4. Comparison between the 13C signals obtained in the mouse head following the injection of either 
hyperpolarized [U-2H7, U-13C6]-D-glucose or hyperpolarized [2,3,4,6,6-2H5, 3,4-13C2]-D-glucose. Zoomed 
carboxyl region in the summed spectra acquired after infusion of hyperpolarized [U-2H7, U-13C2]-D-glucose 
(black) or hyperpolarized [2,3,4,6,6-2H5, 3,4-13C2]-D-glucose (red). The glycolytic intermediates 3PG (179.8 
ppm) and pyruvate (171.1 ppm) can be identified in addition to the lactate peak at 183.5 ppm. The resonances 
marked by (*) are unknown impurities. The 13C-13C coupling pattern collapses to a single peak when replacing 
[U-2H7, U-13C2]-D-glucose by [2,3,4,6,6-2H5, 3,4-13C2]-D-glucose.
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perdeuterated [U-13C] glucose used for the present experiments lowered the quality of the spectra and the low 
SNR of the pyruvate and [1-13C] 3PG signals made it difficult to obtain the time evolution of those two metabo-
lites. Thanks to the high SNR of the [1-13C] lactate signal, ranging from 4.3 to 21.6, we could however record the 
kinetics of the lactate formation (Figs 3 and 5). The lactate-to-pyruvate ratio was calculated for each experiment 
separately by summing the spectra recorded after a single injection of hyperpolarized glucose in each mouse. 
This ratio was quantified in 5 mice, including 3 injected with perdeuterated [U-13C6] glucose and 2 injected with 
[2,3,4,6,6-2H5, 3,4-13C2]-D-glucose, and we obtained a mean value of 17.6 ± 2 (n = 5, mean ± SD).
Discussion
This study reports for the first time that 13C-lactate and 13C-pyruvate signals can be detected in the mouse brain 
as rapidly as 10 s following an i.v. injection of hyperpolarized 13C-glucose despite its relatively short longitudinal 
relaxation time. The lactate-to-pyruvate ratio is in agreement with earlier measurements in the mouse brain28,29 
indicating that after the 50.5 s elapsed from the injection, metabolism had reached steady-state. The blood glucose 
concentration did not exceed the typical values used in glucose tolerance tests30, with a maximum blood concen-
tration of 17 ± 3 mM following injection. The experimental protocol designed for this study includes optimiza-
tion of sample formulation, combined with rapid dissolution and transfer and efficient MRS acquisition scheme 
enabled to dynamically measure lactate formation in the brain in real time during 30 s. The excellent SNR of the 
experiment provides the opportunity to quantify the signal intensities and to define the time evolution of the lac-
tate formation. This kind of data could then be used for modeling to obtain metabolic rates and as an alternative 
to directly quantify CMRglc by MRS31.
An ad-hoc chemical synthesis designed to deuterate and specifically 13C-label the glucose carbons 3 and 4 
was developed for this study. These correspond to the two 13C nuclei labeling the carboxyl group of pyruvate and 
lactate and they have the longest 13C T1 in those metabolites. The similar T1 values of the 3,4-13C2-labeled and 
the uniformly labeled derivatives indicates that 13C homonuclear coupling is not a major source of relaxation. 
Moreover, this synthesis is general and could be used to deuterate any specifically 13C-label glucose that could 
potentially be used as hyperpolarized metabolic probes.
Using specifically 13C-labeled glucose, transfer of the 13C-enriched carbon from glucose to lactate is less 
ambiguous and is not influenced by potential confounding pathways such as the pentose phosphate pathway or 
scrambling of carbons through the various transketolase and transaldolase enzymes. In our case using hyper-
polarized [2,3,4,6,6-2H5, 3,4-13C2]-D-glucose and with the detection at the carboxyl carbon resonances (160–
190 ppm), there is less ambiguity in the peak assignment of the resonance at 179.8 ppm which we have tentatively 
identified as the glycolytic intermediate 3PG. Further investigations will be necessary to confirm this assignment. 
Additionally, it led to a substantial improvement in the 13C MRS SNR mainly due to the absence of 13C-13C 
splitting in the detected metabolic products of [2,3,4,6,6-2H5, 3,4-13C]-D-glucose. It is nevertheless important to 
mention that perdeuterated [U-13C6]-D-glucose has also allowed us to determine the lactate-to-pyruvate ratio 
and to monitor the build-up of lactate, so specific 13C labeling of glucose is not mandatory for all in vivo studies.
Our findings demonstrate that hyperpolarized 13C-glucose might provide complementary kinetic data when 
compared to 18F-FDG PET that provides information on glucose phosphorylation and has been shown to behave 
differently from glucose shortly after injection32. Abnormal glucose metabolism is indeed implicated in several 
Figure 5. In vivo 13C MRS in the mouse head following the injection of hyperpolarized [2,3,4,6,6-2H5, 3,4-13C2]-
D-glucose. Spectra were acquired by applying 20° flip angle at the carboxyl resonances and −0.05° flip angle at 
the substrate resonances every 0.5 s. To improve the SNR every two spectra were added leading to effective time 
resolution of 1 s. Glucose peaks appear at 75.3 ppm (C3-β), 73.8 ppm (C3-α) and 70.7 ppm (C4-α and C4-β) 
and lactate is observed at 183.5 ppm. The corresponding time course (inset) of the spectral data was quantified 
using AMARES.
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diseases, including neurodegenerative diseases33, and the application of the method reported here, perhaps also 
in combination with thermally-polarized 13C-labeled glucose should prove useful in metabolic studies in various 
animal models. Note that for quantitatively assessing real-time glucose cerebral utilization, it may be necessary to 
use a different anesthetic since isoflurane is well known to affect cerebral metabolism34,35.
Methods
Glucose synthesis. [3,4-13C2]-D-glucose (97–98%) was obtained from Cambridge Isotopes Laboratories 
(Tewksbury, Massachusetts) and Omicron Biochemicals Inc. (South Bend, Indiana). [U-2H7, U-13C6]-D-
glucose, deuterium oxide (D, 99.9%) and deuterochloroform (99.8%) were obtained from Cambridge Isotopes 
Laboratories (Tewksbury, Massachusetts). Ruthenium (10% on activated carbon, reduced) was obtained from 
Alfa Aesar. Silica gel (60 Å, 65 × 250 mesh) for flash chromatography was obtained from Sorbent Technologies 
(Norcross, Georgia). The free radical polarizing agent trityl OX063 was obtained from Oxford Instruments 
Molecular Biotools (Tubney Woods, United Kingdom). Other reagents and solvents were obtained from Sigma-
Aldrich (St. Louis, Missouri). All reagents and solvents were used without further purification.
Methyl [3,4-13C2]-D-glucopyranoside (1). Commercially available [3,4-13C2]-D-glucose (1.00 g, 
5.49 mmol) was dissolved in dry methanol (300 mL). Concentrated sulfuric acid (0.500 mL) was added and the 
solution was stirred at reflux (~80 °C bath temperature) overnight. Upon completion and to avoid side reac-
tions due to the presence of concentrated sulfuric acid, the reaction mixture was treated with freshly prepared 
Dowex (1 × 4) anion exchange resin in the hydroxide form to remove excess acid. The beads were then filtered 
and washed with water. The reaction mixture was concentrated by rotary evaporation. The resulting pale-yellow 
syrup was impregnated with silica gel and subjected to flash chromatography with dichloromethane containing 
increasing amount of methanol (7.5% to 15%). The fractions containing the product were combined and evapo-
rated to give a clear syrup (1.00 g, 93% yield). The product was a mixture of the α (60%) and the β (40%) anomers 
as indicated by the NMR data. 1H NMR (600 MHz, D2O) δ 3.21–3.29 (m, βH2), 3.32–3.39 (m, αH3), 3.41 (s, 
αCH3), 3.43–3.55 (βH3, βH4, βH5, αH2), 3.56 (s, βCH3), 3.61–3.65 (br m, αH4, αH5), 3.68–3.79 (αH6a, βH6a,), 
3.85 (br d, J = 12.3 Hz, αH6b), 3.91 (br d, J = 12.3 Hz, βH6b), 4.36 (d, J = 8.0 Hz, βH1) 4.8 (overlapping with HOD 
signal, αH1). 13C NMR (150 MHz, D2O) δ 70.26 (d, JCC = 38.8 Hz, αC4), 70.36 (d, JCC = 39.3 Hz, βC4), 73.80 (d, 
JCC = 38.5 Hz, αC3), 76.47 (d, J = 39.34 Hz, βC3). HRMS (ESI-TOF, positive mode) m/z: [M + H]+ calculated for 
C5 13C2H15O6 197.0936, found [M + H]+: 196.9911.
Methyl [2,3,4,6,6-2H5-3,4-13C2]-D-glucopyranoside (2). Compound 1 (900 mg, 4.59 mmol) was dis-
solved in deuterium oxide (~20 mL). 10 mol % ruthenium on carbon (Ru/C) was added to the solution. The reac-
tion vessel was purged with hydrogen gas and equipped with a hydrogen filled balloon. The reaction was heated 
to 80 °C (bath temperature) and stirred for 24 hours. The reaction mixture was filtered through a Celite S plug and 
washed with copious amounts of methanol. The filtrate was concentrated by rotary evaporation. If NMR indicated 
insufficient deuteration, the hydrogen-deuterium exchange reaction was repeated on the crude pale-yellow syrup 
filtrate. Upon verification of sufficient deuterium incorporation, the pale-yellow syrup was impregnated on silica 
gel and subjected to flash chromatography with dichloromethane containing increasing amount of methanol (5% 
to 15%). The fractions containing the product gave a clear syrup (857 mg, 93% yield). The product was a mix-
ture of the α (65%) and the β (35%) anomers as indicated by the NMR data. 1H NMR (600 MHz, D2O) δ 3.41 (s, 
αCH3), 3.43 (br βH5), 3.56 (s, βCH3), 3.62 (br, αH5), 4.36 (br, βH1), 4.79 (br, overlapping with the HOD signal, 
αH1). 13C NMR (150 MHz, D2O) δ 69.76 (doublet of triplets JCC = 38.5 Hz, JDC = 22.0 Hz, βC4) 69.87 (doublet 
of triplets JCC = 38.8 Hz, JDC = 22.2 Hz, αC4), 73.24 (overlapping doublet of triplets JCC = 38.5 Hz, JDC = 22.1 Hz, 
αC3), 75.89 (overlapping doublet of triplets JCC = 39.1 Hz, JDC = 21.5 Hz, βC3). HRMS (ESI-TOF, positive mode) 
m/z: [M + H]+ calculated for C5 13C2H10D5O6 202.1250; Found 202.0314.
[2,3,4,6,6-2H5, 3,4-13C2]-D-glucose (3). Compound 2 (496 mg, 2.47 mmol) was dissolved in freshly 
prepared 1 M hydrochloric acid (~30 mL). The reaction was heated to ~100 °C (bath temperature) and stirred 
for 5 hours. Upon completion, the solution was concentrated by rotary evaporation. The resulting syrup was 
impregnated with silica gel, and subjected to flash chromatography with dichloromethane containing increasing 
amount of methanol (7.5% to 20%). The fractions containing the product were combined and evaporated to give 
a clear syrup (393 mg, 85% yield) that crystallized on standing. The product was a mixture of the α (35%) and 
the β (65%) anomers as indicated by the NMR data. 1H NMR (600 MHz, D2O) δ 3.43 (br m, βH5), 3.80 (br m, 
αH5), 4.62 (s, βH1), 5.21 (d, J = 5.5 Hz, αH1). 13C NMR (150 MHz, D2O) δ 69.86 (overlapping doublet of triplets 
JCC = 39.3 Hz, JCD = 22.0 Hz, C4), 69.90 (overlapping doublet of triplets JCC = 38.2 Hz, JDC = 22.0 Hz, C4) 72.98 
(doublet of triplets JCC = 38.5 Hz, JDC = 22.0 Hz, αC3), 75.92 (doublet of triplets JCC = 39.1 Hz, JDC = 21.5 Hz, βC3). 
HRMS (ESI-TOF, positive mode) m/z: [M + H]+ calculated for C4 13C2H8D5O6 188.1093; Found 188.0218.
DNP sample preparation. Polarization media was prepared from dissolving trityl radical Ox063 
(tris{8-carboxyl-2,2,6,6-benzo(1,2-d:5-d)-bis(1,3)dithiole-4-yl-methyl sodium salt) in de-ionized water to yield 
concentrations of 35 mM or 40 mM. DNP samples were then prepared by dissolving either [U-2H7, U-13C6]glu-
cose or [2,3,4,6,6-2H5, 3,4-13C2]-D-glucose in 1.1 part polarization medium resulting in final trityl radical con-
centrations of 22 and 25 mM, respectively. The glucose concentrations in these samples were approximately 3 M. 
Note that for this preparation addition of a glassing agent (e.g. glycerol or DMSO) is not needed since glucose in 
high concentration acts as a glassing agent itself.
Dynamic nuclear polarization at 7T/1K. The samples designed for in vivo experiments were all polarized 
at 7 T and and 1 ± 0.05 K using a custom-designed DNP polarizer described in earlier publications25,36. The micro-
wave power at the output of the source was set to 50 mW and the irradiation frequency was set to 196.8 GHz. The 
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nuclear polarization was monitored as a function of time by means of pulsed NMR using 5-degree tipping pulses. 
Following DNP polarization, the hyperpolarized 13C-glucose solutions were rapidly dissolved and transferred 
into an infusion pump placed inside the bore of a 9.4 T imager, with a delay between dissolution and infusion set 
to 3 s37. The pump was programmed to automatically inject 500 µL of the hyperpolarized solution (glucose con-
centration ~100 mM) into a mouse femoral vein.
Animal preparation. All experimental procedures involving mice were approved by the regulatory body 
of the Canton Vaud, Switzerland (Service de la consommation et des affaires vétérinaires) and all experiments 
were conducted according to Federal and local ethical guidelines. Animals were housed in a 12 h light/dark cycle, 
with ad libitum access to food and water and were fasted 12 h prior to the hyperpolarized 13C-glucose injection. 
The glucose blood level before injection were within normal physiological concentrations30 (4.7 ± 1 mM). In vivo 
experiments were performed on C57BL/6 J female mice (20.5 ± 1.5 g). Animals were anesthetized with 1.5% iso-
flurane in a 30% O2/70% N2O mixture and a femoral vein was catheterized for glucose injection. The mouse 
was placed on a holder along with the infusion pump and the femoral vein catheter was connected to the outlet 
of the pump. The holder was then inserted inside the scanner. A bolus of 500 µl of hyperpolarized solution at 
100 mM 13C-glucose concentration was injected within 9 s. The sample contained ~100 µM trityl radical. Mouse 
physiology was monitored and body temperature was maintained throughout the experiment (body temperature 
between 37–38 °C and respiration rate at 100 min−1 by adjustment of the isoflurane dose). All animals were kept 
under anesthesia for a maximum time of 2 h. Glucose blood levels were measured from the tip of the tail before 
the holder was inserted inside the scanner and immediately after the completion of the data acquisition. The ani-
mals were euthanized at the end of each experiment with an overdose of pentobarbital.
In vivo 13C MRS measurements. Measurements were carried out on a Varian INOVA spectrometer 
(Varian, Palo Alto, CA, USA) interfaced to a 31-cm horizontal-bore actively-shielded 9.4T magnet (Magnex 
Scientific, Abingdon, UK). RF transmission and reception were performed with a custom-designed hybrid probe 
consisting of a proton quadrature surface coil and a three-loop 10-mm diameter carbon surface coil placed on the 
top of the mouse head. High order shimming was performed using the FASTESTMAP protocol38. RF excitation 
was performed using 20° selective Gaussian pulses (250 μs/40 kHz bandwidth) centered at 183.5 ppm and applied 
every 500 ms, with effective tilt angle of 1.4° at 95 ppm and −0.05 at 73 ppm. The acquisition time was set to 200 
ms with a spectral bandwidth of 30 kHz. Data was processed using JMRUI39 software and OriginPro®.
Data availability. All data is available from the authors upon reasonable request.
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